ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT

APOQUEL 3.6 mg film-coated tablets for dogs
APOQUEL 5.4 mg film-coated tablets for dogs
APOQUEL 16 mg film-coated tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:
Each film-coated tablet contains:

APOQUEL 3.6 mg 3.6 mg oclacitinib (as oclacitinib maleate)
APOQUEL 5.4 mg 5.4 mg oclacitinib (as oclacitinib maleate)
APOQUEL 16 mg 16 mg oclacitinib (as oclacitinib maleate)

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablets.

White to off-white, oblong shaped film-coated tablets with a score-line on both sides and marked with the letters "AQ" and "S", "M" or "L" on both sides. The letters "S", "M" and "L" refer to the different strengths of tablets: "S" is on the 3.6 mg tablets, "M" on the 5.4 mg tablets, and "L" on the 16 mg tablets.

The tablets can be divided into equal halves.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

Treatment of pruritus associated with allergic dermatitis in dogs.
Treatment of clinical manifestations of atopic dermatitis in dogs.

4.3 Contraindications

Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.
Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

4.4 Special warnings for each target species

None.
4.5 Special precautions for use

Special precautions for use in animals

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored for the development of infections and neoplasia.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

Given the potential for effects on certain clinicopathological parameters (see section 4.6), periodic monitoring with complete blood counts and serum biochemistry is recommended when dogs are on treatment long-term.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after administration.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

The common adverse reactions seen up to day 16 of the field trials are listed in the following table and compared to placebo:

<table>
<thead>
<tr>
<th>Adverse reactions observed in atopic dermatitis study up to day 16</th>
<th>Adverse reactions observed in pruritus study up to day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOQUEL (n=152)</td>
<td>Placebo (n=147)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>4.6%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3.9%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>2.6%</td>
</tr>
<tr>
<td>New cutaneous or subcutaneous lumps</td>
<td>2.6%</td>
</tr>
<tr>
<td>Lethargy</td>
<td>2.0%</td>
</tr>
<tr>
<td>Polydipsia</td>
<td>0.7%</td>
</tr>
</tbody>
</table>

After day 16, abnormal clinical signs, in addition to those clinical signs listed above and occurring in greater than 1% of the dogs receiving oclacitinib included pyoderma, non-specified dermal lumps, otitis, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma, lymphadenopathy, nausea, increased appetite and aggression.

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.

In a laboratory study, the development of papillomas was noted in a number of dogs.
Regarding susceptibility to infection and neoplastic conditions, see section 4.5.

The frequency of adverse reactions is defined using the following convention:
- Very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment).
- Common (more than 1 but less than 10 animals in 100 animals).
- Uncommon (more than 1 but less than 10 animals in 1,000 animals).
- Rare (more than 1 but less than 10 animals in 10,000 animals).
- Very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation, or in breeding male dogs, therefore its use is not recommended during pregnancy, lactation or in dogs intended for breeding.

4.8 Interaction with other medicinal products and other forms of interaction

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight (bw) twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

4.9 Amounts to be administered and administration route

For oral use.

Dosage and treatment schedule:

The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.

These tablets can be administered with or without food.

The dosing table below shows the number of tablets required. The tablets are breakable along the score line.
<table>
<thead>
<tr>
<th>Bodyweight (kg) of dog</th>
<th>Strength and number of tablets to be administered:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APOQUEL 3.6 mg tablets</td>
</tr>
<tr>
<td>3.0–4.4</td>
<td>½</td>
</tr>
<tr>
<td>4.5–5.9</td>
<td>½</td>
</tr>
<tr>
<td>6.0–8.9</td>
<td>1</td>
</tr>
<tr>
<td>9.0–13.4</td>
<td></td>
</tr>
<tr>
<td>13.5–19.9</td>
<td></td>
</tr>
<tr>
<td>20.0–26.9</td>
<td></td>
</tr>
<tr>
<td>27.0–39.9</td>
<td></td>
</tr>
<tr>
<td>40.0–54.9</td>
<td></td>
</tr>
<tr>
<td>55.0–80.0</td>
<td></td>
</tr>
</tbody>
</table>

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Oclacitinib tablets were administered to healthy, one year old Beagle dogs twice daily for 6 weeks, followed by once per day for 20 weeks, at 0.6 mg/kg bw, 1.8 mg/kg bw and 3.0 mg/kg bw for a total of 26 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the feet. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more feet during the study, with the number and frequency of observations increasing with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increasing dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Agents for dermatitis, excluding corticosteroids. ATCvet code: QD11AH90.

5.1 Pharmacodynamic properties

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis. However, oclacitinib may also exert effects on other cytokines (for example, those involved in host defence or haematopoiesis) with the potential for unwanted effects.

5.2 Pharmacokinetic particulars

Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (t\text{max}) of less than 1 hour. The absolute bioavailability of oclacitinib maleate was 89%. The prandial state of the dog does not significantly affect the rate or extent of its absorption.
Total body oclacitinib clearance from plasma was low – 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight. Following intravenous and oral administration, the terminal t½s were similar at 3.5 and 4.1 hours respectively. Oclacitinib exhibits low protein binding with 66.3% to 69.7% bound in fortified canine plasma at nominal concentrations ranging from 10 to 1,000 ng/ml.

Oclacitinib is metabolised in the dog to multiple metabolites. One major oxidative metabolite was identified in plasma and urine.

Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal with IC₅₀s 50-fold greater than the observed mean Cₘₐₓ (333 ng/ml or 0.997 µM) following 0.6 mg/kg bw oral administration in the target animal safety study. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low. No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:
Cellulose, microcrystalline
Lactose monohydrate
Magnesium stearate
Sodium starch glycolate

Tablet coating:
Lactose monohydrate
Hypromellose (E464)
Titanium dioxide (E171)
Macrogol 400 (E1521)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Any remaining half tablets should be discarded after 3 days.

6.4 Special precautions for storage

Store below 25 °C.
Any remaining half tablet should be placed back in the opened blister and stored (for a maximum of 3 days) in the original cardboard carton.

6.5 Nature and composition of immediate packaging

All tablets strengths are packaged in aluminium/PVC/Aclar blisters (each strip containing 10 film-coated tablets) packed into an outer cardboard box. Pack sizes of 20, 50 or 100 tablets.

Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/13/154/001 (1 x 20 tablets, 3.6 mg)
EU/2/13/154/007 (1 x 50 tablets, 3.6 mg)
EU/2/13/154/002 (1 x 100 tablets, 3.6 mg)
EU/2/13/154/003 (1 x 20 tablets, 5.4 mg)
EU/2/13/154/008 (1 x 50 tablets, 5.4 mg)
EU/2/13/154/004 (1 x 100 tablets, 5.4 mg)
EU/2/13/154/005 (1 x 20 tablets, 16 mg)
EU/2/13/154/009 (1 x 50 tablets, 16 mg)
EU/2/13/154/006 (1 x 100 tablets, 16 mg)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 12/09/2013

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
C. STATEMENT OF THE MRLs
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Pfizer Italia S.R.L.
Via del Commercio 25/27
63100 Marino Del Tronto (AP)
ITALY

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARDBOARD CARTON</td>
</tr>
</tbody>
</table>

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

APOQUEL 3.6 mg film-coated tablets for dogs  
APOQUEL 5.4 mg film-coated tablets for dogs  
APOQUEL 16 mg film-coated tablets for dogs

oclacitinib

2. **STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each tablet contains 3.6 mg oclacitinib (as oclacitinib maleate)  
Each tablet contains 5.4 mg oclacitinib (as oclacitinib maleate)  
Each tablet contains 16 mg oclacitinib (as oclacitinib maleate)

3. **PHARMACEUTICAL FORM**

Film-coated tablets

4. **PACKAGE SIZE**

20 tablets  
50 tablets  
100 tablets

5. **TARGET SPECIES**

Dogs

6. **INDICATION(S)**

7. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

8. **WITHDRAWAL PERIOD**

9. **SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.
10. **EXPIRY DATE**

EXP {month/year}

11. **SPECIAL STORAGE CONDITIONS**

Store below 25 °C.
Any remaining half tablet should be stored in the blister and discarded if not used within 3 days.

12. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read the package leaflet.

13. **THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

14. **THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

15. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM

16. **MARKETING AUTHORISATION NUMBER(S)**

EU/2/13/154/001 (1 x 20 tablets, 3.6 mg)
EU/2/13/154/007 (1 x 50 tablets, 3.6 mg)
EU/2/13/154/002 (1 x 100 tablets, 3.6 mg)
EU/2/13/154/003 (1 x 20 tablets, 5.4 mg)
EU/2/13/154/008 (1 x 50 tablets, 5.4 mg)
EU/2/13/154/004 (1 x 100 tablets, 5.4 mg)
EU/2/13/154/005 (1 x 20 tablets, 16 mg)
EU/2/13/154/009 (1 x 50 tablets, 16 mg)
EU/2/13/154/006 (1 x 100 tablets, 16 mg)

17. **MANUFACTURER’S BATCH NUMBER**

Lot
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLISTER</td>
</tr>
</tbody>
</table>

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

- APOQUEL 3.6 mg tablets for dogs
- APOQUEL 5.4 mg tablets for dogs
- APOQUEL 16 mg tablets for dogs
- oclacitinib

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

- Zoetis

3. **EXPIRY DATE**

- EXP {month/year}

4. **BATCH NUMBER**

- Lot

5. **THE WORDS “FOR ANIMAL TREATMENT ONLY”**

- For animal treatment only.
B. PACKAGE LEAFLET
1. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:
Zoetis Belgium SA  
Rue Laid Burniat 1  
1348 Louvain-la-Neuve  
BELGIUM  

Manufacturer responsible for batch release:  
Pfizer Italia S.R.L.  
Via del Commercio 25/27  
63100 Marino Del Tronto (AP)  
ITALY  

2. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

APOQUEL 3.6 mg film-coated tablets for dogs  
APOQUEL 5.4 mg film-coated tablets for dogs  
APOQUEL 16 mg film-coated tablets for dogs  

Oclacitinib  

3. **STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each film-coated tablet contains 3.6 mg, 5.4 mg or 16 mg oclacitinib (as oclacitinib maleate).  
White to off-white, oblong shaped film-coated tablets with a score-line on both sides and marked with the letters "AQ" and "S", "M" or "L" on both sides. The letters "S", "M" and "L" refer to the different strengths of tablets: "S" is on the 3.6 mg tablets, "M" on the 5.4 mg tablets, and "L" on the 16 mg tablets.  
The tablets can be divided into equal halves.  

4. **INDICATION(S)**

Treatment of pruritus associated with allergic dermatitis in dogs.  
Treatment of clinical manifestations of atopic dermatitis in dogs.  

5. **CONTRAINDICATIONS**

Do not use in case of hypersensitivity to oclacitinib or to any of the excipients.  
Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.  
Do not use in dogs with evidence of immune suppression such as hyperadrenocorticism or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.
6. ADVERSE REACTIONS

The common adverse reactions seen up to day 16 of the field trials are listed in the following table and compared to placebo:

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Adverse reactions observed in atopic dermatitis study up to day 16</th>
<th>Adverse reactions observed in pruritus study up to day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APOQUEL (n=152)</td>
<td>Placebo (n=147)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>4.6%</td>
<td>3.4%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3.9%</td>
<td>4.1%</td>
</tr>
<tr>
<td>Lack or loss of appetite (Anorexia)</td>
<td>2.6%</td>
<td>0%</td>
</tr>
<tr>
<td>New cutaneous or subcutaneous lumps</td>
<td>2.6%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Weakness (Lethargy)</td>
<td>2.0%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Excessive thirst (Polydipsia)</td>
<td>0.7%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

After day 16, abnormal clinical signs in addition to those clinical signs listed above and occurring in greater than 1% of the dogs receiving oclacitinib included pyoderma, non-specified dermal lumps, otitis, histiocytoma, cystitis, yeast skin infections, pododermitis, lipoma, enlarged lymph nodes (lymphadenopathy), nausea, increased appetite and aggression.

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.

In a laboratory study, the development of papillomas was noted in a number of dogs.

The frequency of adverse reactions is defined using the following convention:
- Very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment).
- Common (more than 1 but less than 10 animals in 100 animals).
- Uncommon (more than 1 but less than 10 animals in 1,000 animals).
- Rare (more than 1 but less than 10 animals in 10,000 animals).
- Very rare (less than 1 animal in 10,000 animals, including isolated reports).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral use.

Dosage and treatment schedule:
The recommended initial dose of APOQUEL tablets to be given to the dog is to achieve 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy (after the initial 14 days of treatment), the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment by the responsible veterinarian.

These tablets can be administered with or without food.

Please see dosing table below for the number of tablets required to achieve the recommended dose. The tablets are breakable along the score-line.

<table>
<thead>
<tr>
<th>Bodyweight (kg) of dog</th>
<th>Strength and number of tablets to be administered:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APOQUEL 3.6 mg tablets</td>
</tr>
<tr>
<td>3.0–4.4</td>
<td>½</td>
</tr>
<tr>
<td>4.5–5.9</td>
<td>½</td>
</tr>
<tr>
<td>6.0–8.9</td>
<td>1</td>
</tr>
<tr>
<td>9.0–13.4</td>
<td>1</td>
</tr>
<tr>
<td>13.5–19.9</td>
<td>2</td>
</tr>
<tr>
<td>20.0–26.9</td>
<td>2</td>
</tr>
<tr>
<td>27.0–39.9</td>
<td>1</td>
</tr>
<tr>
<td>40.0–54.9</td>
<td>1½</td>
</tr>
<tr>
<td>55.0–80.0</td>
<td>2</td>
</tr>
</tbody>
</table>

9. ADVICE ON CORRECT ADMINISTRATION
Dogs should be carefully observed following administration to ensure that each tablet is swallowed.

10. WITHDRAWAL PERIOD
Not applicable.

11. SPECIAL STORAGE PRECAUTIONS
Keep out of the sight and reach of children.
Store below 25 °C.
Any remaining half tablet should be placed back in the opened blister and stored (for a maximum of 3 days) in the original cardboard carton.
Do not use this veterinary medicinal product after the expiry date which is stated on the blister after EXP.

12. SPECIAL WARNING(S)
Special precautions for use in animals:
Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored for the development of infections and neoplasia.
When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g., flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange). Given the potential for effects on certain clinicopathological parameters (see section 6), periodic monitoring with complete blood counts and serum biochemistry is recommended when dogs are on treatment long-term.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Wash hands after administration.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Use during pregnancy or lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation, or in breeding male dogs, therefore its use is not recommended during pregnancy, lactation or in dogs intended for breeding.

Interaction with other medicinal products and other forms of interaction:
No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasitcides, antimicrobials and anti-inflammatory.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight (bw) twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

Overdose (symptoms, emergency procedures, antidotes):
Oclacitinib tablets were administered to healthy, one year old Beagle dogs twice daily for 6 weeks, followed by once per day for 20 weeks, at 0.6 mg/kg bw, 1.8 mg/kg bw and 3.0 mg/kg bw for a total of 26 weeks. Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital ”cysts”, and oedema of the feet.
Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more feet during the study with the number and frequency of observations increasing with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increasing dose, and was frequently associated with interdigital furunculosis.
Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
14. **DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

15. **OTHER INFORMATION**

APOQUEL tablets are supplied in blister packs with 20, 50 or 100 tablets per pack. Not all pack sizes may be marketed.

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis. However, oclacitinib may also exert effects on other cytokines (for example, those involved in host defence or haematopoiesis) with the potential for unwanted effects.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**
Zoetis Belgium SA
Tél/Tel.: +32 (0)2 746 81 78

**Lietuva**
Zoetis Lietuva UAB
Tel: +370 5 2683634

**Република България**
Zoetis Luxembourg Holding Sarl
Tel: +359 2 970 41 72

**Luxembourg**
Zoetis Belgium SA
Tél/Tel.: +32 (0)2 746 81 78

**Česká republika**
Zoetis Česká republika, s.r.o.
Tel: +420 283 004 111

**Magyarország**
Zoetis Hungary Kft.
Tel: +361 488 3695

**Danmark**
Orion Pharma Animal Health
Tlf: +45 49 12 67 65

**Malta**
Agrimed Limited
Tel: +356 21 465 797

**Deutschland**
Zoetis Deutschland GmbH
Tel: +49 30 330063 0

**Nederland**
Zoetis B.V.
Tel: +31 (0)10 4064 600

**Eesti**
Zoetis Lietuva UAB
Tel: +370 5 2683634

**Norge**
Orion Pharma Animal Health
Tlf: +47 40 0041 90

**Ελλάδα**
Zoetis Hellas S.A.
Τηλ: +30 210 6785800

**Österreich**
Zoetis Österreich GmbH
Tel: +43 1 2701100 110

**España**
Zoetis Spain, S.L.
Tel: +34 91 4909900

**Polska**
Zoetis Polska Sp. z o.o.
Tel: +48 22 335 61 40

**France**
Zoetis France
Tél: +33 (0)1 58 07 46 00

**Portugal**
Zoetis Portugal, Lda.
Tel: +351 21 423 55 00
<table>
<thead>
<tr>
<th>Country</th>
<th>Company Name</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hrvatska</td>
<td>Zoetis Netherlands Holdings BV</td>
<td>+385 1 644 1460</td>
</tr>
<tr>
<td>România</td>
<td>Zoetis România SRL</td>
<td>+40 21 207 17 70</td>
</tr>
<tr>
<td>Ireland</td>
<td>Zoetis Ireland Limited</td>
<td>+353 (0) 1 467 6650</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Zoetis Luxembourg Holding Sarl</td>
<td>+386 (0) 1 52 11 670</td>
</tr>
<tr>
<td>Island</td>
<td>Icepharma hf.</td>
<td>+354 540 80 00</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Zoetis Luxembourg Holding Sarl, o.z.</td>
<td>+421 2 5939 6190</td>
</tr>
<tr>
<td>Italia</td>
<td>Zoetis Italia S.r.l.</td>
<td>+39 06 3366 8133</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Zoetis Finland Oy</td>
<td>+358 (0)9 4300 40</td>
</tr>
<tr>
<td>Kύπρος</td>
<td>Zoetis Hellas S.A.</td>
<td>+30 210 6785800</td>
</tr>
<tr>
<td>Sverige</td>
<td>Orion Pharma Animal Health</td>
<td>+46 (0)8 623 64 40</td>
</tr>
<tr>
<td>Latvija</td>
<td>Zoetis Lietuva UAB</td>
<td>+370 5 2683634</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Zoetis UK Limited</td>
<td>+44 (0) 845 300 8034</td>
</tr>
</tbody>
</table>